Iovance Biotherapeutics

GPTKB entity

Properties (61)
Predicate Object
gptkbp:instanceOf biotechnology company
gptkbp:acquisition TIL_technology_from_the_National_Cancer_Institute
gptkbp:advertising focused on cell therapies
gptkbp:budget published
gptkbp:businessModel cell therapy development
gptkbp:CEO Maria_Fardis
gptkbp:clinicalTrials ongoing
Phase 2
Phase 3
publicly traded
multiple stages
multiple sites
published in journals
analyzed regularly
tumor-infiltrating lymphocyte therapy
gptkbp:collaborations academic institutions
biopharmaceutical companies
ongoing with universities
gptkbp:community_engagement active
gptkbp:community_service engaged with
defined for trials
gptkbp:conference participates in
gptkbp:employeeCount growing
gptkbp:enrollment targeted for therapies
gptkbp:financialPerformance monitored
publicly reported
gptkbp:financials conducted regularly
gptkbp:focus cell therapy
gptkbp:founded 2014
gptkbp:funding secured from investors
gptkbp:future_plans expansion of pipeline
gptkbp:headquarters gptkb:San_Carlos,_California
https://www.w3.org/2000/01/rdf-schema#label Iovance Biotherapeutics
gptkbp:industry operating in
gptkbp:investmentFocus active
various venture capital firms
gptkbp:is_aimed_at gptkb:melanoma
cervical cancer
non-small cell lung cancer
head and neck cancer
gptkbp:market varies
oncology
gptkbp:partnerships various pharmaceutical companies
various organizations
gptkbp:patentCitation filed_for_TIL_technology
gptkbp:patentType pending_for_Lifileucel
gptkbp:products Lifileucel
gptkbp:publications numerous
gptkbp:regulatoryCompliance ongoing
investigational
gptkbp:research focused on TILs
gptkbp:research_areas cancer
gptkbp:research_focus immunotherapy
gptkbp:sells gptkb:NASDAQ
gptkbp:stockSymbol gptkb:IOVA
gptkbp:supplyChain Lifileucel
gptkbp:supportRole established
gptkbp:team experienced professionals
gptkbp:tributaryOf multiple candidates
gptkbp:updates provided regularly
gptkbp:website www.iovance.com